Figure 5
Higher efficacy of metformin antiproliferative effects in NDM29 differentiated neuroblastoma cell populations. A) Cell Index curves of the SKNBE2-S2 and SKNBE-S1 NB cell proliferation untreated (CTR) or treated with metformin (Met), as resulting by Xcelligence RTCA DP analysis. B) Cell Index analysis of SKNBE2-Mock, SKNBE2-S2 and SKNBE2-S1 NB cells untreated (CTR) or treated with metformin (Met), as resulting by Xcelligence RTCA DP analysis. Data were reported as Met/CTR ratio for each cell line. Histogram on the right panel report statistical analysis of 24 and 48 hrs cell index measures. C) Cell counting assay and D) [3H]-thymidine incorporation assay of SKNBE2-Mock, SKNBE2-S2 and SKNBE2-S1 cells untreated (CTR) or treated with metformin (Met). Cell number (C) and cpm (D) values are reported as Met/CTR ratio for each cell type. E) FACS analysis of cell dead with SYTOX blue stain of different cell lines (SKNBE2-Mock, S2, S1). The percentage of cell death is reported as Met/CTR ratio, for each cell type. F) Cell viability determination by ATPlite assay in different cell lines (SKNBE2-Mock, S2 and S1) untreated (CTR) or treated with metformin (Met). Luminescence values, are reported as Met/CTR ratio for each cell type. G) Morphology of S1 cells (scale bar = 200 μm) by EVOS fl, AMG. (*p < 0.05; **p < 0.01; ***p < 0.001).